XML 129 R51.htm IDEA: XBRL DOCUMENT v3.23.2
Schedule of Operations by Reportable Segment (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Segment Reporting Information [Line Items]        
Revenue $ 7,233,000 $ 11,771,000 $ 19,064,000 $ 24,064,000
Interest expense 138,000   388,000  
interest Income 407,000 139,000 538,000 295,000
Net income (loss) from continuing operations (37,723,000) (5,410,000) (46,357,000) (14,361,000)
Capital expenditures 19,000 269,000 613,000 976,000
Identifiable assets 202,744,000 282,948,000 202,744,000 282,948,000
Assets held for sale 2,004,000   2,004,000  
Interest expense 138,000 121,000 388,000 1,499,000
Interest income     538,000  
Stock based compensation       4,000
Operating Segments [Member] | Product Packaging [Member]        
Segment Reporting Information [Line Items]        
Revenue 3,626,000 3,599,000 9,661,000 7,168,000
Interest expense 47,000   86,000  
interest Income 1,000    
Net income (loss) from continuing operations (205,000) 365,000 491,000 323,000
Capital expenditures 4,000 254,000 580,000 943,000
Identifiable assets 23,080,000 26,688,000 23,080,000 26,688,000
Assets held for sale    
Interest expense   34,000   58,000
Interest income      
Stock based compensation       1,000
Operating Segments [Member] | Commercial Banking [Member]        
Segment Reporting Information [Line Items]        
Revenue 197,000 831,000 314,000 960,000
Interest expense    
interest Income    
Net income (loss) from continuing operations (1,213,000) 25,000 (1,777,000) 207,000
Capital expenditures
Identifiable assets 41,324,000 52,416,000 41,324,000 52,416,000
Assets held for sale    
Interest expense    
Interest income      
Stock based compensation      
Operating Segments [Member] | Direct Marketing Online Sales [Member]        
Segment Reporting Information [Line Items]        
Revenue 1,572,000 6,111,000 5,566,000 13,043,000
Interest expense    
interest Income 280,000 2,000    
Net income (loss) from continuing operations (28,074,000) 892,000 (31,260,000) (3,472,000)
Capital expenditures (4,000) 12,000 14,000
Identifiable assets 7,159,000 52,267,000 7,159,000 52,267,000
Assets held for sale 2,004,000   2,004,000  
Interest expense   (321,000)  
Interest income     285,000  
Stock based compensation      
Operating Segments [Member] | Biotechnology [Member]        
Segment Reporting Information [Line Items]        
Revenue 94,000 94,000
Interest expense    
interest Income 49,000 91,000    
Net income (loss) from continuing operations (3,934,000) (673,000) (4,782,000) (1,289,000)
Capital expenditures 12,000 17,000
Identifiable assets 49,952,000 56,524,000 49,952,000 56,524,000
Assets held for sale    
Interest expense    
Interest income     143,000  
Stock based compensation      
Operating Segments [Member] | Securities [Member]        
Segment Reporting Information [Line Items]        
Revenue 1,838,000 823,000 3,523,000 2,497,000
Interest expense 91,000   302,000  
interest Income 78,000 34,000    
Net income (loss) from continuing operations (4,413,000) (3,332,000) (6,441,000) (5,838,000)
Capital expenditures 7,000 2,000 35,000 15,000
Identifiable assets 71,610,000 85,436,000 71,610,000 85,436,000
Assets held for sale    
Interest expense   408,000   1,441,000
Interest income     110,000  
Stock based compensation      
Operating Segments [Member] | Corporate Segment [Member]        
Segment Reporting Information [Line Items]        
Revenue 313,000 302,000
Interest expense    
interest Income 11,000    
Net income (loss) from continuing operations 116,000 (2,687,000) (2,588,000) (4,292,000)
Capital expenditures 1,000 (19,000) 4,000
Identifiable assets 9,619,000 9,617,000 9,619,000 9,617,000
Assets held for sale    
Interest expense    
Interest income      
Stock based compensation       $ 3,000